SCHEMBL7754589

SCHEMBL7754589

Cc1cc2c(cc1C13CC/C(=C/Cc4ccc(C(=O)O)cc4)C1C3)C(C)(C)CCC2(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 17/20 0.51
RXRB P28702 10/20 0.48
RXRG P48443 10/20 0.48
RARA P10276 7/20 0.47
RARB P10826 7/20 0.47
RARG P13631 7/20 0.47
CYP26A1 O43174 2/20 0.45
PPARG P37231 2/20 0.45
MEN1 O00255 1/20 0.45
ABCB11 O95342 1/20 0.45
ESR1 P03372 1/20 0.45
PGR P06401 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CHRM1 P11229 1/20 0.45
DRD1 P21728 1/20 0.45
TBXA2R P21731 1/20 0.45
SLC6A2 P23975 1/20 0.45
ADRA1A P35348 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7754592 1.00 RXRA (0.51) RXRARXRBRXRGRARARARB
SCHEMBL7756267 0.86 RXRA (0.43) RXRARXRBRXRGRARARARB
SCHEMBL7756261 0.86 RXRA (0.43) RXRARXRBRXRGRARARARB
SCHEMBL7757729 0.86 RXRA (0.51) RXRARXRBRXRGRARARARB
SCHEMBL7757722 0.86 RXRA (0.51) RXRARXRBRXRGRARARARB
SCHEMBL7789372 0.86 RXRA (0.51) RXRARXRBRXRGRARARARB
SCHEMBL7789369 0.86 RXRA (0.51) RXRARXRBRXRGRARARARB
SCHEMBL7755022 0.85 RARB (0.53) RXRARXRBRXRGRARARARB
SCHEMBL7755028 0.85 RARB (0.53) RXRARXRBRXRGRARARARB
SCHEMBL7756251 0.81 RXRA (0.46) RXRARXRBRXRGRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010037025-A1 New compounds, their preparation and use MURRAY ANTHONY (DK) 2001-11-01 US claimed
EP-1077919-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP claimed
WO-1999058486-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO claimed
US-20010037025-A1 New compounds, their preparation and use MURRAY ANTHONY (DK) 2001-11-01 US disclosed
EP-1077919-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP disclosed
WO-1999058486-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037025-A1 New compounds, their preparation and use GPR119, SLC5A1, SLC5A2 RXRA 874/4885RXRB 1018/4885RXRG 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.